News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Epsilon Energy declares a $0.0625 quarterly dividend payable Sept 30, signaling cash-flow confidence.
  • S&P moves Hitachi's outlook to positive, signaling an improved credit trajectory.
  • Okta's Q2 beat and strong AI-agent bookings push shares toward a 52-week high.
  • S&P upgrades Teva to BBB-, giving the company investment-grade ratings across major agencies.
  • BMO says Bombardier's sell-off is overdone and raises its price target to C$375.

Latest Articles

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

BridgeBio Pharma announced the presentation of new data on acoramidis, its oral transthyretin stabilizer for treating transthyretin amyloid cardiomyopathy (ATTR-CM), at the ESC Congress 2026. The data reinforce acoramidis as the first-line treatment choice, highlighting survival benefits, improved myocardial functions, and enhanced quality of life.…

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma Corp. announced a modified Dutch auction tender offer to repurchase up to $230 million of its common shares, representing approximately 20.2% to 23.2% of outstanding shares. The offer price range is $5.00 to $5.75 per share, funded from cash on hand following a $178 million settlement payment from Moderna. The tender offer provide…

Crane NXT Announces Appointment of Jason Lund as President of Crane Payment Innovations and Group President of the Detection and Traceability Technologies Segment

Crane NXT Announces Appointment of Jason Lund as President of Crane Payment Innovations and Group President of the Detection and Traceability Technologies Segment

Crane NXT, a global industrial technology company, has appointed Jason Lund as President of Crane Payment Innovations and Group President of its Detection and Traceability Technologies segment. Lund brings extensive experience in leading industrial technology businesses and will focus on growth, operational excellence, and customer innovation withi…

Gogoro Inc. Announces Retirement of Chief Financial Officer and Appointment of Principal Financial Officer

Gogoro Inc. Announces Retirement of Chief Financial Officer and Appointment of Principal Financial Officer

Gogoro Inc., a leader in battery-swapping electric mobility and a Nasdaq-listed company, announced the retirement of its longtime Chief Financial Officer Bruce Aitken effective September 1, 2026. Jacky Lee, with extensive experience in finance and operations, has been appointed as the new Principal Financial Officer. Leadership expressed confidence…

Factory-Built Power: Why Bloom Energy's Modular Fuel Cells Are the Fastest Route to Scale for AI Data Centers

Factory-Built Power: Why Bloom Energy's Modular Fuel Cells Are the Fastest Route to Scale for AI Data Centers

Bloom Energy's factory-built solid oxide fuel cells have become a preferred quick-deploy power source for AI-heavy data centers. With Q2 revenue topping $1.065 billion and a $20 billion backlog, the company is converting scale and product innovation into revenue growth. The stock is richly valued, but the recent pullback and the rollout of Power Co…

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

VERAXA Biotech AG and Secarna Pharmaceuticals announced promising initial results from their collaboration developing antibody oligonucleotide conjugates (AOCs), showing enhanced potency in early in vitro studies. This milestone underscores the therapeutic potential of AOCs to improve targeted treatments for autoimmune and chronic immune diseases. …

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Limited, an innovator in allogeneic cellular therapies, will host a webcast to discuss its FY 2026 financial results and operational updates. The company, with products including the FDA-approved Ryoncil® for steroid-refractory acute graft versus host disease, continues to develop multiple therapies for inflammatory and cardiac conditions…

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Tiziana Life Sciences announced a poster presentation detailing the Phase 2a BANYAN clinical trial of intranasal foralumab for ALS treatment. The trial, part of the Healey ALS MyMatch program, evaluates safety, immune biomarkers, and clinical effects of the investigational therapy, which targets the regulatory T cell pathway to modulate neuroinflam…

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

Ashland Inc. has introduced permexa™ sodium caprate, an intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic, and low-permeability drugs, including GLP-1 agonists. This innovation addresses manufacturing challenges such as formulation consistency and process robustness, and is i…

WRAP: Laser Counter-UAS Technology Added to WrapShield™, Expanding Into DoW, DHS and Tactical Law Enforcement Markets

WRAP: Laser Counter-UAS Technology Added to WrapShield™, Expanding Into DoW, DHS and Tactical Law Enforcement Markets

Wrap Technologies announced an expanded strategic relationship with Frenel Imaging to integrate advanced laser directed-energy counter-UAS technologies into its WrapShield platform, aiming to commercialize across U.S. and NATO markets. This move introduces mobile, scalable laser systems optimized for repeated drone engagements, addressing the evolv…

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Biomea Fusion has completed enrollment in its COVALENT-211 Phase II trial evaluating icovamenib in insulin-deficient type 2 diabetes patients inadequately controlled on antihyperglycemic therapies. The trial enrolled 64 patients, assessing icovamenib's ability to restore beta-cell function and provide durable glycemic control, with topline results …

USA Rare Earth (Nasdaq: USAR) Announces Completion of Upsized $1.55 Billion Capitalization of the U.S. Government-Backed Special Purpose Vehicle (SPV) for Serra Verde Offtake

USA Rare Earth (Nasdaq: USAR) Announces Completion of Upsized $1.55 Billion Capitalization of the U.S. Government-Backed Special Purpose Vehicle (SPV) for Serra Verde Offtake

USA Rare Earth announced the completion of capitalization of a $1.55 billion Special Purpose Vehicle backed by the U.S. Government to purchase 100% of Phase 1 production from Serra Verde, a key rare earth producer. The Department of War committed $750 million, and the Company secured a $500 million senior debt facility, underpinning the acquisition…

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Rapport Therapeutics, a clinical-stage biotech company focused on neurological and psychiatric disorders, announced a virtual key opinion leader (KOL) event for September 22, 2026, to discuss the unmet needs in treating bipolar mania and the development of its lead investigational drug RAP-219. The event will feature expert insights on the limitati…

Descartes Acquires Tai

Descartes Acquires Tai

Descartes Systems Group has acquired Tai, an AI-powered transportation management platform for freight brokers, for approximately $100 million. The acquisition enhances Descartes' transportation management offerings and expands its Global Logistics Network with advanced freight brokerage solutions. Tai’s platform automates freight operations and su…

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics has dosed the first patient in the MODeFIRe-1 Phase 2 clinical trial evaluating its investigational drug MRT-2359 combined with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer (mCRPC). This follows encouraging Phase 1/2 data showing promising clinical responses in this diffic…

Gemini and Apex Fintech Solutions Collaborate to Bring Gemini’s Regulated Crypto Prediction Markets to Apex's Distribution Network

Gemini and Apex Fintech Solutions Collaborate to Bring Gemini’s Regulated Crypto Prediction Markets to Apex's Distribution Network

Gemini and Apex Fintech Solutions have signed a letter of intent for Gemini to become the exclusive CFTC-regulated venue for crypto event contracts distributed through Apex's Futures Commission Merchant to its brokerage clients. This collaboration leverages Gemini’s regulatory milestones to enable brokering both crypto and potentially other event c…

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals announces the appointment of Henry Gosebruch, an experienced biopharmaceutical executive, to its Board of Directors to strengthen corporate strategy and business development as it accelerates its transformation into a leading Rare Disease company. The company also notes a board resignation but retention in executive roles, highl…

Martin Marietta Completes Combination With Lhoist North America

Martin Marietta Completes Combination With Lhoist North America

Martin Marietta Materials, Inc. has completed its acquisition of Lhoist North America, expanding its Specialties platform and positioning itself as the leading limestone producer in the U.S. The transaction strengthens Martin Marietta's asset base with high-quality reserves and broadens its exposure across key industrial end markets such as steel m…